You are here
July 26, 2016
Approach targets autoimmunity
At a Glance
- Researchers developed a strategy to treat a rare autoimmune disease called pemphigus vulgaris and demonstrated its potential in a mouse model.
- The approach may one day provide a flexible strategy to treat autoimmune diseases caused by misdirected antibodies.
The immune system has a variety of cell types that act in unison to protect the body from invading microbial threats. B cells, for example, produce specialized molecules called antibodies that attack harmful microbes. Autoimmune diseases arise when this complex system mistakenly attacks the body’s own tissues.
In people with pemphigus, the cells in the top layer of the skin and the mucous membranes come under immune attack. The immune system mistakenly produces antibodies against proteins known as desmogleins. These proteins help keep skin cells attached and the skin and mucous membranes intact. When desmogleins are attacked, the cells separate from each other and fluid collects in the spaces, forming blisters. The most common type of pemphigus in the United States is pemphigus vulgaris. It arises when B cells make antibodies to desmoglein-3 (Dsg3, also known as keratinocyte adhesion protein).
Pemphigus can be treated with drugs that suppress the immune system or that specifically deplete B cells. However, these approaches can leave the body vulnerable to deadly infections. A team of researchers led by Drs. Aimee S. Payne, Michael C. Milone, and Christoph T. Ellebrecht at the University of Pennsylvania aimed to develop a more selective technique by adapting an emerging approach used to fight cancer. In that approach, immune system T cells are collected from patients and genetically engineered to produce special receptors on their surfaces that recognize a specific protein on tumor cells and attack the cancer.
In pemphigus vulgaris, B cells make specialized receptors that recognize and target the Dsg3 protein. The researchers reasoned they could genetically engineer T cells to express portions of Dsg3, and thus specifically destroy the miscreant B cells without affecting the rest of the immune system. Their work was funded in part by NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Results were published in Science on July 8, 2016.
The team showed in laboratory experiments that human T cells engineered to express portions of Dsg3 killed anti-Dsg3 B cells derived from people with pemphigus vulgaris. The team tested the engineered T cells in a mouse model of pemphigus vulgaris. The engineered cells eliminated anti-Dsg3 B cells from the animals and prevented blisters from forming without any detectable side effects.
With further development, this approach could potentially be used for any autoimmune disease caused by misdirected antibodies. “Our study effectively opens up the application of this anti-cancer technology to the treatment of a much wider range of diseases, including autoimmunity and transplant rejection,” Milone says.
The team is now planning to test the approach in dogs, which can also develop pemphigus vulgaris. “If we can use this technology to cure [pemphigus vulgaris] safely in dogs, it would be a breakthrough for veterinary medicine, and would hopefully pave the way for trials of this therapy in human pemphigus patients,” Payne says.
—by Harrison Wein, Ph.D.
- Autoimmune Disease Super-Regulators Uncovered
- BACH2 Helps Orchestrate the Immune Response
- Shaking Out Clues to Autoimmune Disease
- The Origins of Autoimmunity-Causing T Cells
- Technique Directs Immune Cells to Target Leukemia
- Questions and Answers about Pemphigus
- Autoimmune Diseases
Reference: Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Ellebrecht CT, Bhoj VG, Nace A, Choi EJ, Mao X, Cho MJ, Di Zenzo G, Lanzavecchia A, Seykora JT, Cotsarelis G, Milone MC, Payne AS. Science. 2016 Jul 8;353(6295):179-84. doi: 10.1126/science.aaf6756. Epub 2016 Jun 30. PMID: 27365313.
Funding: NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Cancer Institute (NCI), and National Heart, Lung, and Blood Institute (NHLBI); Penn Institute for Immunology; Dermatology Foundation; Deutsche Forschungsgemeinschaft; and Italian Ministry of Health.